SELDI-TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive pulmonary disease

Clinical Biochemistry

Volumn 43, Issue 1-2, 2010, Pages 168-177

  Gomes Alves, Patrícia ^a   Imrie, Margaret ^b   Gray, Robert D ^b   Nogueira, Paulo ^a   Ciordia, Sergio ^c   Pacheco, Paula ^a   Azevedo, Pilar ^d   Lopes, Carlos ^d   de Almeida, António Bugalho ^d   Guardiano, Micaela ^e   Porteous, David J ^b   Albar, Juan P ^c   Boyd, A Christopher ^b   Penque, Deborah ^a  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^d HOSPITAL DE SANTA MARIA   (Portugal)

^e UNIVERSITY OF PORTO   (Portugal)

Author keywords

Asthma; Biomarkers signatures; CF; COPD; Proteomics; SELDI TOF MS

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CONTROLLED STUDY; CYSTIC FIBROSIS; DIAGNOSTIC VALUE; EPITHELIUM CELL; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NOSE MUCOSA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; AGED; ASTHMA; BIOLOGICAL MARKERS; CYSTIC FIBROSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROTEOMICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; YOUNG ADULT;

EID: 72649099616     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2009.10.006     Document Type: Article

References (34)

1. Collins F.S. Cystic fibrosis: molecular biology and therapeutic implications. Science 256 5058 (1992) 774-779
2. Rosenstein B.J., and Zeitlin P.L. Cystic fibrosis. Lancet 351 9098 (1998) 277-282
3. Welsh M.J., and Smith A.E. Cystic fibrosis. Scientific American 273 6 (1995) 52-59
4. Jeffery P.K. Remodeling in asthma and chronic obstructive lung disease. Am. J. Respir. Crit. Care Med. 164 10 Pt 2 (2001) S28-38
5. Tiddens H., Silverman M., and Bush A. The role of inflammation in airway disease: remodeling. Am. J. Respir. Crit. Care Med. 162 2 Pt 2 (2000) S7-S10
6. Reddy G., and Dalmasso E.A. SELDI ProteinChip(R) Array Technology: protein-based predictive medicine and drug discovery applications. J. Biomed. Biotechnol. 2003 4 (2003) 237-241
7. Macgregor G., Gray R.D., Hilliard T.N., et al. Biomarkers for cystic fibrosis lung disease: Application of SELDI-TOF mass spectrometry to BAL fluid. J Cyst Fibros (2008)
8. Gray R.D., Macgregor G., Noble D., et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. Am. J. Respir. Crit. Care Med. (2008)
9. Petricoin E.F., and Liotta L.A. SELDI-TOF-based serum proteomic pattern diagnostics for early detection of cancer. Curr. Opin. Biotechnol. 15 1 (2004) 24-30
10. Lebrecht A., Boehm D., Schmidt M., Koelbl H., and Grus F.H. Surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry to detect breast cancer markers in tears and serum. Cancer genomics and proteomics 6 2 (2009) 75-83
11. Seibert V., Wiesner A., Buschmann T., and Meuer J. Surface-enhanced laser desorption ionization time-of-flight mass spectrometry (SELDI TOF-MS) and ProteinChip technology in proteomics research. Pathol. Res. Pract. 200 2 (2004) 83-94
12. Engwegen J.Y., Mehra N., Haanen J.B., et al. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab. Investig. J. Tech. Methods Pathol. 87 2 (2007) 161-172
13. Han K.Q., Huang G., Gao C.F., et al. Identification of lung cancer patients by serum protein profiling using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry. Am. J. Clin. Oncol. 31 2 (2008) 133-139
14. Penque D. Proteomic biomarker discovery for the monogenic disease cystic fibrosis. Expert Rev. Proteomics 4 2 (2007) 199-209
15. Penque D., Mendes F., Beck S., et al. Cystic fibrosis F508del patients have apically localized CFTR in a reduced number of airway cells. Lab. Investig. J. Tech. Methods Pathol. 80 6 (2000) 857-868
16. Carvalho-Oliveira I., Efthymiadou A., Malho R., et al. CFTR localization in native airway cells and cell lines expressing wild-type or F508del-CFTR by a panel of different antibodies. J Histochem Cytochem 52 2 (2004) 193-203
17. Grubb B.R., Pickles R.J., Ye H., et al. Inefficient gene transfer by adenovirus vector to cystic fibrosis airway epithelia of mice and humans. Nature 371 6500 (1994) 802-806
18. Davies M.G., Geddes D.M., and Alton E.W. The effect of varying tonicity on nasal epithelial ion transport in cystic fibrosis. Am. J. Respir. Crit. Care Med. 171 7 (2005) 760-763
19. Adkins J.N., Varnum S.M., Auberry K.J., et al. Toward a human blood serum proteome: analysis by multidimensional separation coupled with mass spectrometry. Mol Cell Proteomics 1 12 (2002) 947-955
20. Hsieh S.Y., Chen R.K., Pan Y.H., and Lee H.L. Systematical evaluation of the effects of sample collection procedures on low-molecular-weight serum/plasma proteome profiling. Proteomics 6 10 (2006) 3189-3198
21. Cottingham K. Basic and clinical proteomics researchers: the great divide?. J. Proteome Res. 7 3 (2008) 840-843
22. Beck S., Penque D., Garcia S., et al. Cystic fibrosis patients with the 3272-26A->G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane. Human Mutat. 14 2 (1999) 133-144
23. Hosmer D.W., and Lemeshow D. Applied logistic regression (1989), John Wiley and Sons
24. Miguet L., Bogumil R., Decloquement P., et al. Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. J. Proteome Res. 5 9 (2006) 2258-2269
25. Schagger H. Tricine-SDS-PAGE. Nat Protoc 1 1 (2006) 16-22
26. Moreno S., Ibraghimov-Beskrovnaya O., and Bukanov N.O. Serum and urinary biomarker signatures for rapid preclinical in vivo assessment of CDK inhibition as a therapeutic approach for PKD. Cell cycle (Georgetown, Tex 7 12 (2008)
27. Kozak K.R., Su F., Whitelegge J.P., Faull K., Reddy S., and Farias-Eisner R. Characterization of serum biomarkers for detection of early stage ovarian cancer. Proteomics 5 17 (2005) 4589-4596
28. Yang S.Y., Xiao X.Y., Zhang W.G., et al. Application of serum SELDI proteomic patterns in diagnosis of lung cancer. BMC cancer 5 (2005) 83
29. Bowler R.P., Canham M.E., and Ellison M.C. Surface enhanced laser desorption/ionization (SELDI) time-of-flight mass spectrometry to identify patients with chronic obstructive pulmonary disease. Copd 3 1 (2006) 41-50
30. Tammen H., Schulte I., Hess R., et al. Peptidomic analysis of human blood specimens: comparison between plasma specimens and serum by differential peptide display. Proteomics 5 13 (2005) 3414-3422
31. Benabdeslam H., Abidi H., Garcia I., Bellon G., Gilly R., and Revol A. Lipid peroxidation and antioxidant defenses in cystic fibrosis patients. Clin Chem Lab Med 37 5 (1999) 511-516
32. Laskowska-Klita T., and Chelchowska M. Antioxidant status in erythrocytes of cystic fibrosis children. Acta Biochim. Pol. 48 1 (2001) 283-285
33. Petricoin E.F., Ardekani A.M., Hitt B.A., et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359 9306 (2002) 572-577
34. Zinkin N.T., Grall F., Bhaskar K., et al. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res 14 2 (2008) 470-477